Marina Biotech (MRNA) 0.1400 $MRNA
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French
Marketwired - Thu Jun 02, 8:51AM CDT
BOTHELL, WA--(Marketwired - Jun 2, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announcd that J. Michael French, chairman of the board, president and chief executive officer, is resigning effective June 10, 2016 to pursue other opportunities. Current board member, Joseph W. Ramelli, will assume the roles of chairman of the board and acting chief executive officer. The board of directors is currently conducting a search for a new CEO.
Marina Biotech Provides First Quarter 2016 Financial Reports and Business Update
Marketwired - Tue May 17, 7:01AM CDT
BOTHELL, WA--(Marketwired - May 17, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported recent corporate highlights and financial results for the first quarter 2016.
Marina Biotech to Acquire Late-Stage Program From Turing Pharmaceuticals
Marketwired - Tue May 03, 8:01AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases and Turing Pharmaceuticals AG a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases announced that the companies have executed a term sheet under which Marina intends to acquire Turing's intranasal ketamine program. Pending the negotiation of the definitive agreement, Marina is expected to acquire Turing's intranasal ketamine program for approximately 53 million Marina common shares.
Marina Biotech Provides 2015 Year-End Financials and Update
Marketwired - Thu Mar 31, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported year-end corporate highlights and financial results for 2015.
DNAI: 1.98 (-0.06)
Marina Biotech Announces a License Agreement to Deliver a Genome Editing Technology
Marketwired - Wed Mar 16, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that they have entered into a license agreement covering the company's SMARTICLES and DiLA2 platforms for the delivery of an undisclosed genome editing technology. The agreement is notable in that it provides an exclusive access to Marina's SMARTICLES and DiLA2 platforms for a different gene editing field than was announced on February 17, 2016. This represents the first time that the company's combined delivery platforms, SMARTICLES and DiLA2 technologies, have been licensed in connection with gene editing. Under terms of the agreement, Marina could receive up to $40 MM in success based milestones. Further details of the agreement were not disclosed.
DNAI: 1.98 (-0.06), MIRN: 4.26 (-0.01)
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Marketwired - Tue Mar 15, 7:30AM CDT
Microlin Bio, Inc. (OTCQB: MICB), a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina's nucleic acid therapeutics assets. Pending the negotiation of the definitive agreement and company shareholder approvals, Microlin is expected to acquire Marina's nucleic acid therapeutics assets for 6.7 million common shares and approximately $1 million in cash.
Marina Biotech Reports Clinical and Preclinical Updates From SMARTICLES(R) Licensees Mirna Therapeutics and MiNA Therapeutics
Marketwired - Thu Nov 19, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its SMARTICLES(R) licensee Mirna Therapeutics, Inc. (NASDAQ: MIRN) of Austin, TX, recently announced the presentation of interim results from its ongoing Phase I clinical trial of MRX34, Mirna's lead therapeutic candidate. Mirna's poster presentation was titled, "Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors" and presented on November 8, 2015 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. The poster reported interim Phase I clinical results for MRX34 from 75 patients with advanced solid tumors.
MIRN: 4.26 (-0.01)
Marina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics
Marketwired - Tue Nov 17, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that it received a milestone payment, in the amount of $200,000, from its licensee, MiNA Therapeutics Limited (MiNA), a privately-held biotechnology company pioneering short activating RNA (saRNA) as therapeutic agents for the treatment of human diseases.
Marina Biotech swings to net income of USD0.8m for Q3 2015
M2 - Tue Nov 17, 3:26AM CST
Drug company Marina Biotech (OTCQB:MRNA) stated on Monday that it recorded a net income of USD0.8m for the three months ended 30 September 2015.
Marina Biotech Announces Third Quarter 2015 Financial Results
Marketwired - Mon Nov 16, 4:00PM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three and nine months ended September 30, 2015.
Marina Biotech Reports That Licensee ProNAi Therapeutics Initiates 'Brighton' Phase II Trial of PNT2258 in Patients With Richter's Transformation
Marketwired - Tue Nov 03, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, Inc. (NASDAQ: DNAI) has enrolled the first patient into the "Brighton" study, a Phase II clinical trial evaluating PNT2258 in patients with Richter's transformation. The international multi-center trial is expected to enroll approximately 50 patients with this rare form of cancer for which there are currently no approved therapies. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES(R) delivery technology.
DNAI: 1.98 (-0.06), MIRN: 4.26 (-0.01)
Marina Biotech and Hongene Biotechnology Announce License Agreement
Marketwired - Mon Sep 28, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases and Hongene Biotechnology Limited announced that they have entered into a License Agreement where Hongene will have exclusive rights to develop, supply and commercialize certain oligonucleotide amidites using Marina's Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina will receive royalties from the sale of CRN-based reagents. Moreover, this Agreement will establish a ready supply of CRN amidites for Marina's therapeutic research and development effots.
Marina Biotech Announces Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 4:00PM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended June 30, 2015.
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marketwired - Thu Aug 06, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.
Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis
Marketwired - Wed Aug 05, 3:30PM CDT
Marina Biotech, Inc. (OTCQB: MRNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CEQ508, an investigational RNAi therapeutic for the treatment of Familial Adenomatous Polyposis (FAP). Currently, there is no pharmaceutical approach available to treat FAP, which affects an estimated one in 10,000 people worldwide and is associated with a near 100% risk of colon cancer if untreated. In addition, the company announced the allowance of US 13/196,436 covering the tkRNAi delivery technology -- the delivery technology for CEQ508 -- in the U.S. The patent broadly covers a wide range of vectors for bacterial mediated gene silencing, as well as the fundamental invasive bacterium for delivering RNA therapeutics.
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French
Marketwired - Thu Jun 02, 8:51AM CDT
BOTHELL, WA--(Marketwired - Jun 2, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announcd that J. Michael French, chairman of the board, president and chief executive officer, is resigning effective June 10, 2016 to pursue other opportunities. Current board member, Joseph W. Ramelli, will assume the roles of chairman of the board and acting chief executive officer. The board of directors is currently conducting a search for a new CEO.
Marina Biotech Provides First Quarter 2016 Financial Reports and Business Update
Marketwired - Tue May 17, 7:01AM CDT
BOTHELL, WA--(Marketwired - May 17, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported recent corporate highlights and financial results for the first quarter 2016.
Marina Biotech to Acquire Late-Stage Program From Turing Pharmaceuticals
Marketwired - Tue May 03, 8:01AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases and Turing Pharmaceuticals AG a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases announced that the companies have executed a term sheet under which Marina intends to acquire Turing's intranasal ketamine program. Pending the negotiation of the definitive agreement, Marina is expected to acquire Turing's intranasal ketamine program for approximately 53 million Marina common shares.
Marina Biotech Provides 2015 Year-End Financials and Update
Marketwired - Thu Mar 31, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported year-end corporate highlights and financial results for 2015.
DNAI: 1.98 (-0.06)
Marina Biotech Announces a License Agreement to Deliver a Genome Editing Technology
Marketwired - Wed Mar 16, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that they have entered into a license agreement covering the company's SMARTICLES and DiLA2 platforms for the delivery of an undisclosed genome editing technology. The agreement is notable in that it provides an exclusive access to Marina's SMARTICLES and DiLA2 platforms for a different gene editing field than was announced on February 17, 2016. This represents the first time that the company's combined delivery platforms, SMARTICLES and DiLA2 technologies, have been licensed in connection with gene editing. Under terms of the agreement, Marina could receive up to $40 MM in success based milestones. Further details of the agreement were not disclosed.
DNAI: 1.98 (-0.06), MIRN: 4.26 (-0.01)
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Marketwired - Tue Mar 15, 7:30AM CDT
Microlin Bio, Inc. (OTCQB: MICB), a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina's nucleic acid therapeutics assets. Pending the negotiation of the definitive agreement and company shareholder approvals, Microlin is expected to acquire Marina's nucleic acid therapeutics assets for 6.7 million common shares and approximately $1 million in cash.
Marina Biotech Reports Clinical and Preclinical Updates From SMARTICLES(R) Licensees Mirna Therapeutics and MiNA Therapeutics
Marketwired - Thu Nov 19, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its SMARTICLES(R) licensee Mirna Therapeutics, Inc. (NASDAQ: MIRN) of Austin, TX, recently announced the presentation of interim results from its ongoing Phase I clinical trial of MRX34, Mirna's lead therapeutic candidate. Mirna's poster presentation was titled, "Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors" and presented on November 8, 2015 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. The poster reported interim Phase I clinical results for MRX34 from 75 patients with advanced solid tumors.
MIRN: 4.26 (-0.01)
Marina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics
Marketwired - Tue Nov 17, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that it received a milestone payment, in the amount of $200,000, from its licensee, MiNA Therapeutics Limited (MiNA), a privately-held biotechnology company pioneering short activating RNA (saRNA) as therapeutic agents for the treatment of human diseases.
Marina Biotech swings to net income of USD0.8m for Q3 2015
M2 - Tue Nov 17, 3:26AM CST
Drug company Marina Biotech (OTCQB:MRNA) stated on Monday that it recorded a net income of USD0.8m for the three months ended 30 September 2015.
Marina Biotech Announces Third Quarter 2015 Financial Results
Marketwired - Mon Nov 16, 4:00PM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three and nine months ended September 30, 2015.
Marina Biotech Reports That Licensee ProNAi Therapeutics Initiates 'Brighton' Phase II Trial of PNT2258 in Patients With Richter's Transformation
Marketwired - Tue Nov 03, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, Inc. (NASDAQ: DNAI) has enrolled the first patient into the "Brighton" study, a Phase II clinical trial evaluating PNT2258 in patients with Richter's transformation. The international multi-center trial is expected to enroll approximately 50 patients with this rare form of cancer for which there are currently no approved therapies. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES(R) delivery technology.
DNAI: 1.98 (-0.06), MIRN: 4.26 (-0.01)
Marina Biotech and Hongene Biotechnology Announce License Agreement
Marketwired - Mon Sep 28, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases and Hongene Biotechnology Limited announced that they have entered into a License Agreement where Hongene will have exclusive rights to develop, supply and commercialize certain oligonucleotide amidites using Marina's Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina will receive royalties from the sale of CRN-based reagents. Moreover, this Agreement will establish a ready supply of CRN amidites for Marina's therapeutic research and development effots.
Marina Biotech Announces Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 4:00PM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended June 30, 2015.
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marketwired - Thu Aug 06, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.
Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis
Marketwired - Wed Aug 05, 3:30PM CDT
Marina Biotech, Inc. (OTCQB: MRNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CEQ508, an investigational RNAi therapeutic for the treatment of Familial Adenomatous Polyposis (FAP). Currently, there is no pharmaceutical approach available to treat FAP, which affects an estimated one in 10,000 people worldwide and is associated with a near 100% risk of colon cancer if untreated. In addition, the company announced the allowance of US 13/196,436 covering the tkRNAi delivery technology -- the delivery technology for CEQ508 -- in the U.S. The patent broadly covers a wide range of vectors for bacterial mediated gene silencing, as well as the fundamental invasive bacterium for delivering RNA therapeutics.
